NCT00584402

Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: University of California, Davis · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas \& metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography

Detailed description

An estimated 75 patients (age 18 years of age or older) will be enrolled from the population of patients who present for ultrasound-guided radiofrequency ablation (RFA) of CT or MRI-confirmed multiple primary hepatocellular carcinoma (HCC) or metastatic carcinoma, with at least one of the tumors being ≤ 1.5 cm in diameter.

Conditions

• Liver Neoplasms

Interventions

Type	Name	Description
DRUG	perflutren lipid microspheres	perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity

Timeline

• Start date: 2007-04-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-01-02
• Last updated: 2017-07-11
• Results posted: 2017-07-11

Locations

1 site across 1 country: United States